Investors

19 May 2025

Archer partners with Paragraf for Biochip development

→

12 May 2025

Partnership extended with QMUL

→

7 May 2025

Presentation - Semiconductor Conference 2025

→

5 May 2025

Appointment of Company Secretary

→

16 April 2025

Quarterly Activity Report & Appendix 4C

→

9 April 2025

12CQ Quantum Program Presentation- RMIT Quantum Industry Day

→

31 March 2025

AXE partners with Hylid Diagnostics for Biochip development

→

27 March 2025

Appointment of Chief Executive Officer

→

26 February 2025

Appendix 4D and Half Year Financial Report

→

13 February 2025

Precision spin state control for next-generation qubits

→

22 January 2025

Archer Granted Key Biochip Patent

→

17 January 2025

Quarterly Activity Report & Appendix 4C

→

8 January 2025

Breakthrough in Quantum Carbon Films for Qubit Realisation

→

16 December 2024

Response to ASX Price Query Letter

→

16 December 2024

Response to ASX Price Query Letter

→

2 December 2024

Change in substantial holding from AXE

→

28 November 2024

Biochip moves toward feasibility & improved testing accuracy

→

27 November 2024

Archer receives $2.1 million R&D Tax Incentive rebate

→

25 November 2024

Archer receives prototype TMR sensors from foundry partner

→

20 November 2024

Change of Director's Interest Notice x 3

→

20 November 2024

Notification regarding unquoted securities - AXE

→

20 November 2024

Notification regarding unquoted securities - AXE

→

20 November 2024

Notification of cessation of securities - AXE

→

20 November 2024

Results of 2024 Annual General Meeting

→

20 November 2024

AGM Presentation

→

11 November 2024

Investor Presentation

→

8 November 2024

TMR sensor project presentation

→

7 November 2024

Miniaturised Biochip gFET design improves foundry readiness

→

31 October 2024

Invitation to attend presentation

→

30 October 2024

Archer's 12CQ Quantum Project Hits Key Milestone

→

23 October 2024

Semiconductor Australia Conference - Presentation

→

18 October 2024

Notice of Annual General Meeting/Proxy Form

→

14 October 2024

Departure of CEO (update)

→

10 October 2024

Agreement signed with foundry to manufacture TMR sensors

→

4 October 2024

Quarterly Activity Report & Appendix 4C

→

30 September 2024

Archer develops new manufacturable carbon quantum material

→

3 September 2024

Proof of concept devices to improve 12CQ chip spin detection

→

28 August 2024

2024 Corporate Governance Statement and Appendix 4G

→

27 August 2024

Biochip experiments begin to develop kidney disease testing

→

26 July 2024

Quarterly Activity Report & Appendix 4C

→

23 July 2024

New Biochip gFET test procedure and process developed

→

18 July 2024

Quantum technology project update

→

15 July 2024

Management restructure

→

12 July 2024

Departure of CEO

→

28 June 2024

Notification of cessation of securities - AXE

→

17 June 2024

Archer Biochip gFET design fabricated on a six-inch wafer

→

9 May 2024

Notification of cessation of securities - AXE

→

29 April 2024

Quarterly Activity Report & Appendix 4C

→

9 April 2024

Change in substantial holding from AXE

→

5 April 2024

Sharecafe Investor Presentation

→

2 April 2024

Change of Director's Interest Notice

→

2 April 2024

Notification of cessation of securities - AXE

→

25 March 2024

Archer and EPFL develop a single chip pulsed ESR microsystem

→

11 March 2024

Archer miniaturises Biochip gFET chip design

→

16 February 2024

Appendix 4D and Half Year Financial Report

→

24 January 2024

Quarterly Activity Report & Appendix 4C

→

16 January 2024

Notification of cessation of securities - AXE

→